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Abstract 
Mitochondria are controlled by the coordination of two genomes: the mitochondrial and the nuclear DNA. As such, 
variations in nuclear gene expression as a consequence of mutations and epigenetic modifications can affect mito‑
chondrial functionality. Conversely, the opposite could also be true. However, the relationship between mitochondrial 
dysfunction and epigenetics, such as nuclear DNA methylation, remains largely unexplored.Mitochondria function 
as central metabolic hubs controlling some of the main substrates involved in nuclear DNA methylation, via the 
one carbon metabolism, the tricarboxylic acid cycle and the methionine pathway. Here, we review key findings and 
highlight new areas of focus, with the ultimate goal of getting one step closer to understanding the genomic effects 
of mitochondrial dysfunction on nuclear epigenetic landscapes.
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Background
Mitochondrial diseases and population prevalence
Mitochondria display the distinctive feature of being the 
only mammalian cellular organelle containing an inde-
pendent genome, the mitochondrial DNA (mtDNA). This 
DNA can be found in different copy numbers depending 
on the cell and tissue type, rendering mtDNA as poly-
plasmic. Quantities can range from around  103 to  104 
genomes per cell, yet still only representing 1% of the 
total cellular DNA [1]. Mammalian mtDNA is a circu-
lar double-stranded molecule of approximately 16.6  kb 
in size [1] that encodes only 37 genes, 13 of which are 
respiratory chain subunits and 24 being RNA compo-
nents, such as tRNAs and rRNAs [1, 2]. It is estimated 
that mitochondria contain approximately 1500 differ-
ent proteins, indicating that the vast majority of these 
are being encoded by the nuclear genome and imported 
into mitochondria [1]. Pathogenic mutations can occur in 
both nuclear DNA (nDNA) and mtDNA, with the mito-
chondrial genome presenting a mutational rate 100 fold 
higher than that of the nuclear genome, in turn leading to 
the heterogenous nature of inheritance of mitochondrial 
diseases [3]. Varying disease penetrance, as well as the 
occurrence and accumulation of spontaneous mutations 
in either genomes, contributes to an ever-expanding phe-
notypic spectrum [3]. Together, the variance in clinical 
expression and the multisystemic nature of these diseases 
has led to poor diagnosis and prognosis of mitochondrial 
diseases. These disorders cause significant morbidity and 
mortality, with a total of 1 in 4300 adults presenting with 
a mitochondrial ailment, and with these conditions being 
among the commonest inherited forms of neurological 
diseases [3]. Careful clinical and biochemical characteri-
zation of such pathological phenotypes is key for detec-
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In the last few decades, advances in next-generation 
sequencing and non-invasive diagnostic methods have 
started to transform our understanding of mitochondrial 
diseases. Nevertheless, comprehending the complexities 
of the mechanisms behind these pathologies remains elu-
sive. It is speculated that one layer of intricacy of varying 
mitochondrial disease penetrance could involve differen-
tial DNA methylation (DNAm). Genomic DNA methyla-
tion is a highly conserved mechanism that plays a pivotal 
role in development, tissue specification and diseases like 
cancer and neurodegeneration [4, 5], where methylation 
of certain cytosines can alter gene expression.
Mitochondrial genomics and metabolism have been 
studied in the context of DNA methylation. Cells har-
bouring distinct mitochondrial haplogroups and mtDNA 
polymorphisms have been shown to present differences 
in nDNA methylation [6–8]. Moreover, as many metabo-
lites are produced in the mitochondria but transit to the 
nucleus, alterations in their levels have been found to 
influence the efficiency of enzymes and affect the produc-
tion of substrates required for methylation [9, 10]. The 
focus of this review is to discuss the relationship between 
mitochondria and the nucleus on an epigenetic level 
centred on DNA methylation (summarized in Fig.  1). 
Advances in the field shall be considered, remaining open 
questions will be proposed, and cause and effect versus 
association discussions have been instigated. Elucidat-
ing and debating these may be key to the development of 
future treatments, guide more specific clinical prognosis 
and form more comprehensive prevention strategies.
What is DNA methylation and why is it important?
DNA methylation entails the conversion of cytosine to 
5-methylcytosine (5mC), predominantly due to a DNA 
methyltransferase (DNMT) enzyme transferring a methyl 
group from S-adenosyl-methionine (SAM) to the 5th 
carbon of the ring of cytosine. This conversion is usually 
found within CpG dinucleotide sites (regions of the DNA 
in which a cytosine nucleotide is immediately followed 
by a guanine nucleotide in a linear sequence in the 5′ to 
3′ direction [11]) despite occurrences also in non-CpG 
methylation sites [4]. Such epigenetic DNA modifications 
occur in intronic, exonic and intergenic regions [12], and 
are involved in the regulation of gene expression, either 
via interaction with promoters, enhancers, transcription 
factors and gene bodies, or via stimulating transcrip-
tional elongation and gene splicing [12, 13].
Fig. 1 Interactions between DNA methylation and mitochondria. Arrows refer to different phenomena. (1) nDNAm: Nuclear DNA methylation 
impact on mitochondrial metabolism. (2) nDNA expression: Influence of nuclear gene expression on enzymes which may cause mtDNA 
methylation. (3) Metabolites: Effect of mitochondrial metabolites on nDNA methylation. (4) mtDNA SNPs: Burden of mtDNA mutations and 
haplogroups on nDNA methylation. Metabolites are presented in purple; DNA methylation sites are shown in yellow; DNA mutations are displayed 
in pink; orange refers to enzymes
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With age, genome-wide levels of methylation are 
reported to generally decrease overall across multiple tis-
sues (referred to as hypomethylation) [14, 15], but also 
specifically in certain tissues, e.g., in blood and brain [4], 
particularly in repetitive elements of intergenic regions 
[16]. Conversely, promoter-associated CpG islands 
present increased DNA methylation (known as hyper-
methylation) [17]. More explicitly, gene ontology (GO) 
analyses of genes with differential methylation due to 
aging have found hypermethylation to occur significantly 
in biological processes involved in cell-to-cell signal-
ling, and development, while hypomethylation studies 
have shown enrichment in mechanisms correlated with 
mRNA and protein metabolism, immune responses, and 
mitosis [18].
In humans, alterations in DNA methylation levels in 
coding regions are associated with one-third of muta-
tions that cause diseases in the germline [13, 19]. The 
mutational rate of methylated cytosines involving transi-
tions to thymine has been shown to be more than 40-fold 
higher compared to random mutations. This suggests 
that DNA methylation can also contribute to the inci-
dence of pathology via permanently changing the DNA 
sequence [15, 19]. Apart from its connection to develop-
mental disorders, DNA methylation has been found to 
occur in many different human diseases originating due 
to somatic malignant changes, ranging from cancers to 
neurodegenerative and psychotic disorders (for a detailed 
review refer to [11]). Interestingly, DNA methylation also 
plays an important role in preserving genomic stability, 
as methylation of CpGs in transposons, retrotransposons 
and repetitive sequences prevent the expression of these 
elements [20].
The importance of nDNA methylation in disease pene-
trance is evident from studies of monozygotic twins, who 
share an identical genetic background, but distinct epige-
netic alteration [21, 22]. Such investigations reveal clear 
phenotypic variations between the individuals, including 
that of predisposition to pathological conditions, such 
as neurodegeneration, cancer, and autoimmune diseases 
[20].
Global DNAm progressively diverges and changes dur-
ing a person’s lifetime and ageing. Still, some changes in 
locus-specific DNAm sites have been found to be highly 
reproducible independently of gender and tissue being 
analysed, and hence can be used as a measure for age. 
Intrinsically, global DNAm levels have been recently 
described as a biomarker of chronological age. This bio-
marker estimate is known as the epigenetic clock or DNA 
methylation age [23], where measurements in sorted 
cells, tissues and organs [14, 24] are made independent 
of classic risk factors while still being able to predict all-
cause mortality [23].
Ageing is characterized by an overall decrease in 
DNAm across most tissues. This global genomic hypo-
methylation has also been found in a number of different 
human cancers [25], as has locus-specific hypermethyla-
tion. A notable example is caused by increased DNAm in 
the promoter region of the gene P16—a common cause 
for development of human cancers due to epigenetic 
events [25]. Furthermore, differential DNAm correlates 
with neurodegenerative disorders with Alzheimer’s dis-
ease (AD) patients suffering from global hypomethyla-
tion [26, 27]. More specifically, studies have described 
inhibited DNMTs leading to cognitive impairment and 
disease progression [26].
Mitochondrial diseases are no exception to the list of 
human diseases speculated to have an epigenetic com-
ponent, with examples involving pathologies caused by 
mtDNA mutations leading to LHON (Leber’s hereditary 
optic neuropathy) [28], and non-syndromic deafness 
due to the m.1555A > G mutation [29, 30]. While genetic 
in origin, some studies hypothesize on the involvement 
of an epigenetic component which can at times exacer-
bate these phenotypes. In many of such studies, the exact 
epigenetic link is still unclear, rendering these connec-
tions as of yet merely understood as environmental fac-
tors. This is the case for LHON in which environmental 
factors, often referred to as mutagenic elements, such 
as carbon monoxide [31], cigarette smoke, alcohol [28], 
and also the antituberculosis medication ethambutol 
[32] have been presented as components that can induce 
more severe symptoms for that specific disease and hence 
have the potential to be directly or indirectly epigenetic 
or genetic processes. To our knowledge, the mechanisms 
behind how environmental factors influence the onset or 
development of these disorders are still unknown. One 
conjecture could involve an epigenetic modification, such 
as DNAm of the mitochondrial genome affecting the 
expression and function of intramitochondrial enzymes, 
while another speculation might revolve around nuclear 
genes being influenced by epigenetic alterations lead-
ing to changes in mitochondrial functionality. Another 
mitochondrial disease debated to have an epigenetic 
component is non-syndromic deafness. Research in 
mice and human cancer cell lines have shown an asso-
ciation between rRNA hypermethylation, an activation 
of the proapoptotic transcription factor E2F1 and faulty 
mitochondrial biogenesis in respect to two mitochon-
drial regulatory proteins: the rRNA methyltransferase-
related human mitochondrial transcription factors B1 
(h-mtTFB1) and B2 (h-mtTFB2) [30, 33, 34]. Few mito-
chondrial diseases have been studied directly in relation 
to epigenetics, in particular DNA methylation, rendering 
this an important field open for exploration. It is likely 
that a limited number of studies around this topic are 
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related to the complexity surrounding untangling mito-
chondrial diseases and metabolism, and understanding 
its cause or effect relationship to epigenetics. Constraints 
imposed by current technology, despite rapidly evolving 
over the last 20 years, imply that mtDNA sequencing as 
of yet cannot be carried out in parallel to methodolo-
gies to measure DNA methylation, at least not on a sin-
gle cell level. Still, studies could begin with sequencing 
to measure DNAm and the mitochondrial genome on 
a multicellular tissue or cell type level, in either human 
mitochondrial disease patients or animal models. The lat-
ter presents advantages in terms of facilitating the main-
tenance of environmental aspects, and stability of nDNA 
backgrounds, and thus, encouraging longitudinal investi-
gations. This could commence the detailed dissection of 
this relationship with the aim to define genes and pro-
teins that may be involved in any causative links.
Effects of nuclear DNA methylation 
on mitochondria
Nuclear DNA methylation can impact the expression 
level of nuclear-encoded genes and nuclear-encoded 
mitochondrial genes. While the former group of genes 
perform a variety of cytoplasmic, organelle-specific and 
even extracellular functions, the latter group of genes are 
translated into proteins and enzymes that are specifically 
required for mitochondrial transcription and replica-
tion, and the mitochondrial respiratory chain complex 
[35]. A seminal example of abnormally increased DNA 
methylation levels altering mitochondrial functionality 
is that of the nuclear-encoded mitochondrial gene DNA 
polymerase gamma (POLG). In particular, methylation 
at the catalytic subunit A (POLGA), which is important 
for mtDNA replication and embryogenesis, has been 
negatively correlated with mtDNA copy numbers. This 
increased methylation was observed in differentiating 
embryonic stem cells and reflects the process of estab-
lishing the ‘mtDNA set point’ from which mitochondria 
expand in a cell-specific manner [36]. Likewise, DNA 
demethylation increases the expression of many factors 
involved in mtDNA replication like TOP1MT and POLG, 
consequently elevating the levels of mitochondrial copy 
numbers in glioblastoma cells [37]. Alterations in DNAm 
can additionally be found in genes associated with oxida-
tive phosphorylation (OXPHOS) in disease or with age. 
Such is the case in human patients with autism spectrum 
disorder (ASD) presenting differences in methylation 
of the genes encoding for complex I, such as NDUFA4, 
NDUFB2, NDUFB4 and NDUFB6, complex III, like 
UQCRC2, and complex IV, for instance COX7B [38]. 
Likewise, complex IV methylation alterations are also 
seen in non-diseased elderly human muscle tissue [39] 
and in laboratory high fat diet-induced insulin resistance 
rats [40], in the genes COX7A1 and Cox5a, respectively. 
These studies illustrate the paramount impact nuclear 
DNAm has on mitochondria, in terms of mtDNA con-
tent and mitochondrial functionality.
Is mitochondrial DNA methylated?
Since the 1970s, whether methylation occurs in the 
mtDNA has been a topic of debate [41–43]. Experimenta-
tion on frogs and HeLa cells indicated that mitochondria 
lack the machinery necessary for DNAm [41]. Neverthe-
less, measurements of 5-methylcytosine levels, the most 
abundant DNA methylation modification, have revealed 
that this epigenetic modification does indeed occur in the 
organelle but at lower levels than in the nucleus, rang-
ing from one-fourth to one-fourteenth of that found in 
nDNA [42]. Still, different methodologies for measure-
ments, including CpG- or non-CpG-specific sites, vary-
ing mtDNA regions assayed, including the L- (light) and 
H- (heavy) strand composition of mtDNA, and the dif-
fering cell types investigated have predicted mtDNA 
methylation approximations to range from 1 to 20% [44]. 
Several studies mainly employing bisulfite sequencing in 
human [45] and in mouse [46] have questioned the pres-
ence of mtDNA methylation, implying, for example, that 
secondary structures of mtDNA and its circular structure 
may be causing overestimations of methylation signals 
[44]. Consequently, while some claim that mtDNA meth-
ylation levels are too low to be considered significant and 
current techniques are too biased to be reliable, others 
claim that mtDNA is methylated differently to nDNA, in 
this case in a strand-specific manner [15], only in non-
CpG sites, yet at quantifiable levels [15, 47]. Notwith-
standing, this topic remains highly debated.
Despite the fact that functional roles of mtDNA meth-
ylation remain unknown [35], other nuances have been 
detected. Absolute quantities of CpG dinucleotides in 
mtDNA relative to other species have been reported to be 
smaller than expected if there were no factors influencing 
these CpG sites [48]. Additionally, specific patterns of CG 
dinucleotide rich areas can be seen in the mtDNA, with 
as many as 50% of these being found in polymorphic var-
iants. This uneven distribution raises questions regarding 
the possibility that mtDNA methylation might have taken 
place.
Still, DNMTs and ten-eleven translocation (TETs), 
which are enzymes instrumental in DNA methylation and 
demethylation, respectively, usually found in the nucleus, 
have been spotted in the mitochondria, and present an 
apparent influence on mtDNA methylation. DNMT1 has 
been observed to translocate into the mitochondria and 
interact with the mtDNA in the matrix of some tissues 
such as mouse embryonic fibroblasts, human colon carci-
nomas [35], and human brain cells [49]. In fact, DNMT1 
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mutations can lead to development of two neurodegen-
erative diseases known as autosomal dominant cerebellar 
ataxia-deafness and narcolepsy (ADCA-DN) and heredi-
tary sensory neuropathy with dementia and hearing loss 
(HSN1E). Importantly, both syndromes display clinical 
features typical of known mitochondrial diseases, like 
optic atrophy, peripheral neuropathy, deafness, and mito-
chondrial dysfunction [50]. Interestingly, some nuclear 
encoded proteins involved in mitochondrial function, 
such as PGC1a and NRF1 (acting in a complex or alone), 
or P53, can up-regulate or down-regulate, respectively, 
the levels of intra-mitochondrial DNMT1 (mtDNMT1) 
[35]. These genes can also be found to be methylated, 
with PGC1a modifications affecting mitochondrial den-
sity in type 2 diabetic patients [51, 52], and NRF1 methyl-
ation causing TFAM (mitochondrial transcription factor 
A) silencing and a reduction in mitochondrial biogenesis 
[53]. In fact, methylation of PGC1a can additionally be 
modulated by nuclear DNMT3 [52] or DNMT1, the lat-
ter of which can be inhibited by AMPK (AMP-activated 
protein kinase) phosphorylation [54]. These studies 
raise the question of whether differential methylation of 
nuclear genes controlling the expression and activity of 
DNMT1 may also indirectly lead to changes in mtDNA 
methylation.
DNMT1 is not the only DNMT to be found in the 
mitochondria. While studying ALS (amyotrophic lateral 
sclerosis) in mouse, another neurological disease affect-
ing voluntary muscle movements, researchers have found 
the presence of the enzyme DNMT3A in the CNS (cen-
tral nervous system), striated muscle and testes of these 
animals, and reinforced these findings by detecting the 
same enzyme in mitochondria of human cerebral cor-
tex [49, 55]. Similar results were also seen in another 
study which discusses the expression of the same gene in 
mitochondria of mouse and human CNS [49]. Levels of 
Dnmt3a were found to be significantly lower in skeletal 
muscle and spinal cord of these mouse models present-
ing early disease signs, and these appear concomitantly 
to abnormal patterns of DNA 5mC [55]. Nonetheless, 
DNMT3A is not the only DNMT3 found to act in mito-
chondria. DNMT3B can modify the frequency and quan-
tity of mtDNA methylation in healthy breast cells, albeit 
in a strand specific manner, affecting the L-strand more 
significantly. The importance of DNMT enzymes was 
further confirmed in knockdown studies with DNMT3B 
and DNMT3A, leading to reductions in global mtDNA 
methylation [47] and regional mtDNA methylation [15], 
respectively. Additionally, when comparing the effects of 
knocking down Dnmt1, Dnmt3a and Dnmt3b in mouse 
embryonic stem cells, all of these presented an analogous 
mtDNA methylation pattern while remaining lower than 
wild type samples [56].
When discussing the presence of DNMT enzymes 
in the mitochondria, it is worth noting the isoform of 
the enzyme. While earlier reports [35] inferred that 
DNMT1-isoform1 localized to the mitochondria, a more 
recent study contradicts such claim and instead puts 
forward DNMT1-isoform3 as being able to translocate 
to the mitochondria and methylate the mtDNA [57]. In 
fact, different isoforms also play a role in the presence 
of DNMT3A in mitochondria, as shorter isoforms like 
78 kDa Dnmt3a can be found expressed primarily in skel-
etal muscle, while longer isoforms of 100 kDa are found 
expressed mostly in the nervous tissue [55]. These results 
suggest that the presence of these enzymes and the dif-
fering levels of mtDNA methylation are tissue specific. It 
might be postulated that the presence of these enzymes 
required for this epigenetic change, particularly in spe-
cific tissues, might be functionally linked to the expres-
sion of specific mitochondrial genes, raising the question 
of whether mtDNA methylation could regulate certain 
genes in accordance with cellular and metabolic demand.
Other enzymes involved in modulation of 5mC in 
mtDNA have been detected in mitochondria too, 
namely TET enzymes. Despite unknown mechanisms 
of translocation to the mitochondria, TET1 and TET2 
enzymes have been found to be present in mouse neu-
ronal mitochondria, for example in the cerebellum and 
Purkinje cells of aged animals [58]. Moreover, the expres-
sion of Tet2 and Tet3, once increased, is associated with 
increased levels of 5hmC  (5-hydroxymethylcytosine) 
found both in the nuclear and mitochondrial DNA [58, 
59]. While providing indications that TET enzymes could 
have a role in mtDNA methylation, the exact functioning 
of such enzymes is yet to be elucidated.
Recent studies have started to focus on addressing 
concerns of measuring mtDNA methylation raised in 
a number of investigations [38–41]. New methodolo-
gies have been presented which are specifically adapted 
to mitochondrial genomes to improve bisulfite conver-
sion of mtDNA [47], and adapted to the analysis and 
methylation calling for this particular genome [15], yet 
do still acknowledge the limitations of some of these 
adaptations. One such example involves the fragmenta-
tion of the mtDNA via sonication in order to overcome 
secondary structures which could skew bisulfite conver-
sion. Despite this adjustment, the technique produces a 
range of sizes of DNA fragments, many of which can be 
found in the small range of 100-200 bp, hence becoming 
prone to degradation, causing important loss of informa-
tion [47]. Another study suggests that biases found in 
mtDNA methylation calling are not caused intrinsically 
by bisulfite treatment, but rather due to an inherent bias 
in the L- and H-strands of the mtDNA, likely due to the 
former strand carrying 12 of the 13 protein-coding genes 
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of the mitochondria, backing up these claims by carrying 
out analyses also using a non-bisulfite method [15].
Still, despite the much-heated contrast of opinions 
on the topic, this discussion should not derail from the 
potential debates that could stem off the possibility that 
mtDNA methylation does indeed happen. Could poten-
tial DNMT and TET-modulated mtDNA methylation 
influence the expression levels of mitochondrial-encoded 
genes and their respective functionalities? If so, could 
this phenomenon loop back into affecting the nucleus 
and its DNA? Further interrogation of these questions 
could shed light on disease penetrance and phenotypic 
variability of mitochondrial diseases.
Effects of mitochondria on nuclear DNA 
methylation
Effects of mitochondrial DNA
Signals from the mitochondria to the nucleus are referred 
to as ‘the retrograde response’ and can control the expres-
sion of nuclear genes in order to regulate mitochondrial 
functionality and metabolism [2]. Recently, research 
suggested that mtDNA variants play a part in the link 
between mitochondria and nuclear DNAm. In studies 
using peripheral adult human blood, articular cartilage, 
and human retinal cell cybrids, which possess identi-
cal nuclei but different mtDNA, diverse haplogroups 
have been shown to present differing degrees of nDNA 
methylation [6, 7, 60]. This is the case for haplogroup J 
which has consistently been associated with higher lev-
els of DNA methylation when compared to other hap-
logroups such as H in cybrids and cartilage cells [7, 60], 
and also U, X and T in blood [6]. Likewise, mtDNA hap-
lotypes of mouse embryonic stem cells also present dis-
tinct DNAm patterns [61]. Haplotypes are described as a 
group of DNA variations that are inherited together and 
have accumulated with time due to maternal inheritance 
and the lack of recombination, while haplogroups refer 
to mtDNA polymorphism variations that are found in a 
group of similar haplotypes. Additionally, this has been 
observed in brains of mouse models containing iden-
tical nDNA yet varying mtDNA polymorphisms [62]. 
Removal of mtDNA in  Rh0 cells further confirms these 
results, where abnormal methylation patterns in nDNA 
genes were partially restored to normal with re-inser-
tion of the mitochondrial genome [63], thus suggest-
ing that disruptions or mutations in mtDNA can result 
in epigenetic changes in nDNA. Future insights into the 
interplay between mtDNA and nDNA methylation could 
involve the study of mitochondrial heteroplasmy. In fact, 
recent findings suggest that epigenetic histone meth-
ylation is regulated by mtDNA heteroplasmy [64, 65]. 
Defining the mechanisms involved in such phenomena 
could be important to determine mitochondrial disease 
penetrance.
Since mtDNA-depleted  (Rh0) cells exhibit minimal 
amounts of ATP (adenosine triphosphate) and a decline 
in nDNA methylation [6], and similarly, cybrid cells of 
the J haplogroup present lower levels of ATP compared 
to non-J cybrids [6, 8]; it has been claimed that ATP lev-
els regulated by mtDNA are correlated with a decrease 
in global DNAm [6]. Studies indicate that the reduced 
ATP levels observed in the J haplogroup could be asso-
ciated with problems in the mitochondrial respiratory 
complex. Variants clustered in the J haplogroup often fall 
within complex I (ND1) and complex III (cytochrome b), 
with some groups reporting single nucleotide polymor-
phisms (SNP) causing loss of structural integrity of ND1, 
a drop in oxygen consumption, or partial uncoupling of 
OXPHOS [6]. As such, J haplogroup has been found to 
have functional consequences on several complex traits 
like LHON, multiple sclerosis, neurodegeneration and 
longevity [66]. Haplogroup J has also been associated 
with significantly lower levels of MBD2 in comparison 
with haplogroup H [7]. This gene is part of a family of 
proteins that bind to methylated DNA and block tran-
scription, ultimately, being associated with a number of 
conditions such as cancers [7]. Differential expression of 
these genes could also lead to variation in nuclear DNAm 
and transcription and subsequently affect inflammation 
pathways, which are activated in certain diseases, for 
example leading to the higher incidence of age-related 
macular degeneration seen in J haplogroup patients [7]. 
Similarly, other mitochondrial haplogroups have also 
been associated with increased risk of a number of differ-
ent traits. Yet still, an in-depth study of the relationship 
between the J haplogroup and DNAm is lacking. Moreo-
ver, detailed studies on the impact of other haplogroups 
on DNA methylation are also limited.
Finally, the impact of mitochondrial respiratory com-
plex dysfunctions on DNAm is starting to appear. Nota-
ble examples are seen in studies where rotenone-induced 
complex I dysfunction resulted in global changes in 
DNAm levels in rats, human cybrid cells, and even when 
induced in mother mice and measured in the offspring 
[64, 65, 67, 68]. Together, these studies enforce the notion 
that differences in mtDNA are signalled to the nucleus, 
influencing its DNA, and are consequently associated 
with nuclear DNAm [6, 69]. Whether these associations 
are correlative or causational remains to be elucidated. 
Further investigations on global and regional changes in 
DNAm using other drugs known to affect the mitochon-
drial respiratory complex, as well as studies involving 
animal models with mtDNA mutations for interrogating 
mitochondrial diseases, are warranted to initiate forging 
the way towards understanding the cause and effect link.
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Effects of mitochondrial metabolites
Mitochondrial haplotypes and haplogroups affect a vari-
ety of signalling pathways. Some studies imply an effect 
of these variants on nuclear DNAm and suggest that this 
could be due to mitochondria influencing pathways such 
as OXPHOS, the methionine cycle [6, 8, 61], inflamma-
tion and angiogenesis [7]. In fact, recent findings suggest 
that mitochondrial dysfunction and mtDNA variations 
can cause alterations in metabolite levels, consequently 
interfering with nuclear DNAm. A tight interlinked net-
work of metabolic pathways affecting DNA methylation 
involves the mitochondria (Fig. 2). These include, but are 
not restricted to: serine biosynthesis, the folate cycle, the 
methionine cycle, the transsulfuration pathway, and the 
Krebs cycle.
The folate cycle, also known as the one-carbon (1C) 
cycle, which mainly takes place in the mitochondria, 
entails the transfer of one carbon from either serine or 
glycine for the formation of DNA and RNA building 
blocks, or the generation of methionine. Subsequently, 
this pathway is linked to the methionine cycle, found 
in the cytoplasm, which is involved in the produc-
tion of SAM, a methyl donor that is used for numerous 
reactions, including DNAm [70]. SAM is produced by 
methionine adenosyltransferase reacting with methio-
nine and ATP. Once having lost its methyl group, SAM 
becomes SAH (S-adenosyl-homocysteine), which is 
converted into homocysteine, and can later be turned 
back to methionine, restarting the cycle, or feed into 
the transsulfuration pathway where it becomes irrevers-
ibly transformed [71]. The latter leads to the production 
of cysteine and α-ketobutyrate, both necessary for glu-
coneogenesis, a metabolic process that makes glucose 
from non-carbohydrate carbon sources. Interestingly, the 
levels of SAM have been found to be dependent on the 
mitochondrial haplogroup. One such example is seen in 
human cybrid cell lines of haplogroup J cells which have 
a higher expression level of methionine adenosyltrans-
ferase 1A (MAT1A), hence elevated levels of global meth-
ylation, when compared to the same cell types with H 
haplogroup [6].
Antagonistic to this mechanism is glycolysis, a pro-
cess that uses cytoplasmic glucose for the production of 
energy together with the Krebs cycle, which takes place 
in the mitochondria. The latter pathway uses acetyl-CoA, 
which is produced from the end product of glycolysis 
Fig. 2 Metabolic processes tightly intertwined with DNA methylation. The yellow pathway refers to the folate cycle which mainly takes place in 
the mitochondria, and generates methionine. The red cycle is the methionine cycle which is important for the production of SAM in the cytoplasm. 
The blue network represents DNA methylation, and highlights the modification that happens on the genome, for example, in the nucleus. The 
transsulfuration pathway shown in green involves the irreversible transformation of homocysteine, leading to gluconeogenesis which takes place in 
the mitochondria, cytosol and the endoplasmic reticulum
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known as pyruvate, and undergoes a series of modifi-
cations producing intermediates like α-ketoglutarate, 
succinate and fumarate (Fig.  3). These metabolites all 
influence the activity of TET enzymes, which in fact 
belong to the family of α-ketoglutarate-dependent deoxy-
genases [9], and hence, require α-ketoglutarate to func-
tion. Succinate and fumarate, on the other hand, as seen 
in multiple human cancerous cell lines, are inhibitors of 
TET enzymes, and in the case of fumarate, it is capable 
of modulating TET also via reducing mRNA expression 
of TET1 and TET2, though increasing mRNA expression 
of TET3 enzymes [10]. Additionally, the activity of TET 
enzymes also changes in response to AMPK-mediated 
phosphorylation (Fig.  3). This is in turn dependent on 
glucose levels in mice and humans, with hyperglycaemic 
conditions impeding the phosphorylation, thus alter-
ing the quantities of 5hmC, the first oxidative product 
of the demethylation of 5mC [72]. Additionally, AMPK 
can also enhance the expression of TET enzymes directly 
or via increasing isocitrate dehydrogenase 2 (IDH2), a 
mitochondrial enzyme found in the Krebs cycle involved 
in the production of α-ketoglutarate, and hence acti-
vate TETs to ultimately decrease DNAm. Interest-
ingly, AMPK plays a dichotomous role when it comes 
to DNMT enzymes. While it presents an inhibitory role 
towards DNMT1, it can also have a stimulatory effect 
on DNMT3s. The latter takes place as AMPK either 
transactivates let-7 microRNA which leads to an increase 
in the SAM/SAH ratio, or it activates serine hydroxy-
methyltransferase 2 (SHMT2) which converts serine 
to glycine in the mitochondria, facilitating production 
of SAM [54] (Fig. 3). In both scenarios, increased SAM 
activates DNMT3s, thus altering normal methylation 
patterns. This has been shown to be the case, in humans 
after exercise, for the methylation of promoters of genes 
like COX4I (cytochrome C oxidase subunit 4I1) [54]. This 
gene plays an important role in the transfer of electrons 
from complex III to complex IV in the mitochondrial 
respiratory chain; and exemplifies how mitochondrial 
metabolism can impact nuclear DNAm, and subse-
quently mitochondrial functionality.
Given the interlinked relationship of these pathways, 
alterations to any one or many of these processes can 
affect DNAm levels. An unbalance in the 1C metabolism 
has the potential to impact cell cycle, transcription, rep-
lication and signalling via the regulation of nucleotide 
pools, redox and methylation status, although the pre-
cise mechanism coming from the mitochondria remains 
elusive. Similarly, little is known about how mitochon-
drial dysfunctions bring on modifications in the mito-
chondrial folate pool and serine biosynthesis, despite 
the involvement of mammalian target of rapamycin 
(mTOR) and the activating transcription factor 4 (ATF4) 
[73]. In human cells with reduced mtDNA or during 
Fig. 3 Interaction of Krebs cycle intermediates and AMPK with DNA methylation. Diagram shows how cytoplasmic glycolysis connects to the Krebs 
cycle, which occurs in the mitochondria. The latter affects the levels of TETs that are involved in DNA methylation, and which are regulated also by 
AMPK. AMPK modulates DNA methylation via DNMT directly and indirectly, and by interacting with the Krebs cycle. Different colours refer to the 
terms metabolic processes (green), DNA processes (purple), metabolites (blue), enzymes (yellow), proteins (red) and miRNA (black)
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experimental respiratory chain blockade [73], ATF4 has 
been shown to be responsible for increasing the expres-
sion of genes involved in the production of serine, in an 
attempt to maintain the 1C pathway functioning. ATF4, 
once activated by mTOR, also has the ability to regulate 
the mitochondrial folate pool in cells with mitochondrial 
myopathy [74]. In these same mammalian cells, mTOR 
can additionally coordinate the induction of 1C-depend-
ent pathways, including the folate cycle, serine biosynthe-
sis, transsulfuration, and dNTP synthesis [74]. Alongside 
this, loss of mtDNA causes perturbations to the Krebs 
cycle, igniting a response in the methionine and polyam-
ine metabolism separately, perhaps due to their contribu-
tions to succinate [75], but also impacting the methionine 
cycle through the polyamine metabolism, independently 
of serine-driven 1C metabolism or transsulfuration [75]. 
Moreover, depletion of mtDNA can lead to the activa-
tion of serine biosynthesis, folate pool remodelling, and 
to a shift in the 1C metabolism [63] towards transsulfura-
tion, thus leading to the generation of cysteine that will 
be used for gluconeogenesis [75]. While precise mecha-
nistic links between these pathways are still missing, 
current studies pinpoint to the complexity of the level of 
intertwining between these cycles. Likewise, the Deletor 
mouse strain lacking the mtDNA helicase Twinkle, and 
hence deficient in replication, also presents alterations in 
these pathways. In this scenario, the metabolic changes 
were found to be due to increases in the levels of cho-
line and betaine, which are involved in the conversion 
of homocysteine to methionine, and ornithine that later 
becomes methylthioadenosine (MTA) also involved in 
the regulation of methionine [76].
Methionine is crucial for DNAm due to its require-
ment for the production of SAM, which consequently is 
needed by DNMT for the methylation of cysteine resi-
dues on DNA. As an essential amino acid [77] with high 
significance in DNAm, it has previously been speculated 
that increasing its dietary intake could increase DNAm 
[78]. In fact, methionine supplementation in rats influ-
ences tissue-specific nDNA methylation levels, indicative 
of a non-uniform response to this 1C metabolic substrate 
[79]. While confirming an involvement of methionine in 
nDNA methylation levels, further research is required 
to better understand the extent of its involvement and 
whether it could indeed be used to reverse DNAm altera-
tions in the clinic [80].
In the absence of methionine in human colorectal 
cancer cells, the serine biosynthesis pathway provides 
one-carbon units to the methionine cycle, allowing 
homocysteine to be converted to methionine. In paral-
lel, regardless of the methionine status, the serine cycle 
is involved in DNAm as it is important and rate-limit-
ing in de novo ATP synthesis which is required for the 
generation of SAM from methionine [70]. The way in 
which the serine biosynthesis pathway divides its con-
sumption of one-carbon units between nucleotide syn-
thesis, more specifically purine, and homocysteine 
remethylation, can be controlled by serine hydroxymeth-
yltransferase (SHMT1). The demand for serine is met via 
a combination of exogenous serine uptake and generation 
from intracellular glucose. Like serine, other amino acids 
and metabolites maintain their levels stable by diet and 
cellular metabolism, as is the case for methionine. Yet, as 
previously described, simply altering just one factor is an 
underestimate of its impacts, since methionine has also 
been classified as the most toxic amino acid and can lead 
to the formation of methanethiol-cysteine disulfides that 
cause methionine toxicity if supplied in excess to small 
animals like chickens, rats and quails [81].
Collectively, the current state of research on the inter-
action between mitochondrial metabolism and nuclear 
DNAm highlights a number of gaps in our knowledge. 
This is likely due to the complexity of the various path-
ways, how tightly interlinked they function, and the fact 
that some genes have various roles regarding DNAm, 
some of which are dichotomous. Moreover, it is appar-
ent that DNAm and metabolic differences are organism-, 
tissue- and cell-type specific, perhaps due to the inher-
ently different mitochondrial needs of each subtype, 
which might stem off which donors for the 1C are used, 
and how 1C substrates are metabolized in every case [73, 
82]. Different techniques are currently employed in an 
attempt to unravel such complexities, including but not 
limited to liquid chromatography and mass spectrom-
etry, multi-omics like proteomics and metabolomics, 
and most recently, MITO-Tag which is available in vitro 
as well as in  vivo for mice, allowing for the rapid isola-
tion of cell-type specific mitochondria from tissues [83]. 
Despite these novel approaches, untangling this synergy 
as of now, can only be considered as the beginning of a 
long, exciting process.
Conclusions and future perspectives
Limited treatments for mitochondrial diseases due to 
its wide spectrum of clinical phenotypes and variable 
penetrance have led to the development of mitochon-
drial replacement therapy (MRT). This technique has 
enabled mothers that are carriers of mtDNA mutations 
leading to debilitating mitochondrial syndromes to have 
children without transmitting their maternal disease-
causing mtDNA. Despite the immeasurable possibili-
ties this procedure has provided, it also raises concerns 
about the reciprocal interaction between the nucleus and 
mitochondria. While the efficient replacement of mutant 
mtDNA in oocytes have resulted in embryos with > 99% 
of donor mtDNA, some embryonic stem cells derived 
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after the therapy have demonstrated a gradual loss of 
the donor mtDNA, presenting a reversal to the original 
mitochondrial haplotype observed in the oocyte pre-
treatment [84]. Incompatibility of nuclear and mitochon-
drial genomes is not a new topic, leading to impacts on 
the physiological fitness of the offspring shown for exam-
ple in studies carried out in yeast, Drosophila and mice 
[85], although not yet seen in humans and non-human 
primates [86]. Epigenetic factors like DNA methylation 
have not yet been addressed in this context. While MRT 
remains an uncommon treatment, further investigations 
into the interplay between the newly replaced mitochon-
dria and the oocyte’s nucleus, including DNA methyla-
tion, may aid in the prevention of unanticipated caveats 
in future newborns.
DNAm is implicated in a wide range of diseases includ-
ing cancer, diabetes, neurodegenerative disorders, and 
mitochondrial pathologies. A multitude of techniques 
have been employed to study this link, ranging from 
methylation-specific PCR and pyrosequencing, to meth-
ylation arrays and whole genome bisulfite sequencing. 
Still, results remain correlative instead of causative. While 
correlative studies are important, in order to interro-
gate causational links, recent investigations have started 
to use statistical inference to assess causality of their 
experiments. Mendelian randomization, a method that 
uses measurements of genes of known functionality to 
examine the causal effect of another putative variable for 
a given disease, has become one of the most commonly 
used analysis to enable unbiased estimates. Proving the 
usefulness of this approach, causality of DNAm of spe-
cific CpG sites has been linked to increased risks of dis-
orders like cardiovascular disease, type 2 diabetes, and 
Parkinson’s disease [87].
Development of single-cell DNAm techniques along-
side the possibility to use cells from formalin-fixed and 
paraffin-embedded tissue directly from patients has also 
offered potential for growth of this field [88]. The use of 
individual cells has created the opportunity not only to 
assess heterogeneous systems and rare cell types, but 
has generated the ability to use very low input materials, 
hence bringing more clinical applications within reach. 
This fast-developing technology has allowed for the 
simultaneous analysis of multiple aspects of a mere cell 
including, but not limited to: gene expression, DNAm, 
chromatin accessibility, copy number variation, and gen-
otype [89]. This young field has opened the possibility to 
integrate different layers of information with the promise 
to create a clearer picture of the role of DNAm, for exam-
ple, in reference to mitochondrial diseases and aging.
Aging is also highly correlated with mitochondrial 
function, as an accumulation of mtDNA mutations can 
lead to a reduction in functionality of the mitochon-
drial respiratory chain. In fact, studies carried out on 
the mtDNA mutator mouse which harbour a number 
of different somatic mutations, show that these ani-
mals present various aging phenotypes such as osteo-
porosis, weight reduction, hair loss, greying of hair, 
and loss of fertility [90]. Importantly, the majority 
of human age-related diseases have a mitochondrial 
component to them, in particular neurodegenera-
tive diseases. Recent developments in measuring age 
through DNAm have created the opportunity to inves-
tigate these three seemingly independent elements: 
mitochondrial parameters, DNAm profile, and age. 
Chronological and biological age (measured via dif-
ferent DNAm age clocks [91]) from tissues and most 
importantly blood samples of mitochondrial diseased 
patients can be studied in terms of DNA methyla-
tion, making personalized medicine, and preventive 
care, now, a more realistic proposition. Together, these 
three elements may create a holistic picture that could 
lead to the better understanding of mitochondrial dis-
eases, improved diagnostic abilities and more tailored 
therapeutic strategies.
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